The University of Pittsburgh is conducting a $420,685 project grant titled "Accelerated Neuromodulation of Prefrontal Circuitry During Clozapine Treatment" funded by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242). This two-year project seeks to explore the use of accelerated intermittent theta burst stimulation (iTBS) to enhance working memory and functional connectivity in individuals with treatment-resistant...
This federal Project Grant award of $816,604 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to determine the extent to which two specific neuromarkers moderate responses to repetitive transcranial magnetic stimulation (rTMS) treatments for substance use disorders (SUDs). The research project will use a phased approach to first assess whether a reward reactivity neuromarker (Aim 1) and a cognitive control neuromarker (Aim...
This $1,585,991 Project Grant award from the National Institute on Drug Abuse (NIDA) under the CFDA 93.279 Drug Use and Addiction Research Programs is supporting a double-blind randomized clinical trial to evaluate the efficacy of combining transcranial direct current stimulation (tDCS) over the dorsolateral prefrontal cortex with cognitive reappraisal training in reducing craving and improving inhibitory control in individuals with cocaine use disorder. The study, conducted by the Icahn...
This Project Grant from the National Institutes of Health National Institute on Drug Abuse will fund Neurobehavioral Research Inc. to provide network synchrony neurofeedback training and evaluation for opioid dependent individuals receiving medication assisted treatment. The $807,960 award, issued on September 30, 2021, will support 12 neurofeedback sessions over 8 weeks to train participants' brains to mimic adaptive changes in resting state brain network synchrony seen with long-term...
This Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) will explore the use of Temporal Interference (TI) electrical neurostimulation as a non-invasive method for deep brain stimulation. The $420,519 award, effective May 15, 2025 through May 14, 2027, will characterize the effects of TI on brain activity and functional connectivity through combined TI and fMRI in human subjects (Aim 1). It will then apply TI to...
The National Institute on Drug Abuse (NIDA) awarded a $319,278 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Photopharmics, Inc. to develop a novel, non-pharmacological whole body vibration (WBV) device to treat anxiety, craving, and opioid use associated with opioid use disorder (OUD). The project aims to improve the technical aspects of the WBV device, evaluate physiological indices of anxiety, and implement telemetry to control and record from the device....
The U.S. National Institute of Neurological Disorders and Stroke (NINDS) awarded a $399,954 Project Grant to Highland Instruments Inc. under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to expand the commercialization readiness of its Electrosonic Stimulation (ESStiM) technology. ESStiM is a noninvasive brain stimulation modality developed by Highland Instruments to treat chronic pain associated with carpal tunnel syndrome. The grant funding will enable Highland Instruments to...
This federal Project Grant award from the National Institute of Mental Health (NIMH) under CFDA 93.242 Mental Health Research Grants provides $147,656 to Beth Israel Deaconess Medical Center, Inc. to develop a data-driven framework for mapping the effects of transcranial electrical stimulation on audiovisual integration and hallucinations. The key objectives of the project are to: 1) Determine if neural correlates of audiovisual integration are engaged by cathodal high-definition transcranial...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $3,565,780 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop a groundbreaking high-frequency trans-spinal magnetic stimulation (HF-TSMS) system for the non-invasive treatment of neuropathic pain. The funded project aims to create an HF-TSMS tool that can target neural pathways involved in...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $2,359,174 Project Grant under the 21st Century Cures Act - Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research on the biophysical mechanisms of cortical microstimulation. The project aims to develop a more mechanistic understanding of how direct local electrical stimulation...